Description
FOXO4-DRI 10mg – Senescent Cell and FOXO4–p53 Interaction Research Australia
FOXO4-DRI 10mg is a designed D-retro-inverso research peptide listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled experimental research.
FOXO4-DRI has attracted scientific interest because of its association with cellular senescence, FOXO4–p53 protein interactions, apoptosis-associated signalling and experimental senescent-cell biology.
Cellular senescence is a biological state in which cells undergo a relatively stable withdrawal from the cell cycle while remaining metabolically active.
Senescent cells can exhibit changes in gene expression, stress signalling and inflammatory mediator production.
These changes are relevant to research involving ageing-associated tissue biology, cellular stress and tissue homeostasis.
FOXO4 is a member of the forkhead box O family of transcription factors, which participate in cellular stress responses and other regulatory processes.
The p53 protein is a major regulator of cellular responses to DNA damage, stress, cell-cycle arrest and apoptosis.
Published preclinical research has investigated the interaction between FOXO4 and p53 in senescent cells.
FOXO4-DRI was designed as an experimental peptide intended to interfere with this interaction.
Cell-based and animal studies have explored whether disrupting the FOXO4–p53 interaction can alter senescent-cell survival and senescence-associated tissue responses.
However, experimental observations involving senescent cells do not establish that FOXO4-DRI reverses ageing, extends lifespan, restores tissue function or safely removes senescent cells in humans.
The compound’s long-term safety, clinical efficacy and relevance to human disease remain unestablished.
Peps Aussie lists FOXO4-DRI in a nominal 10mg size for laboratory research and analytical applications.
Important: FOXO4-DRI is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, anti-ageing applications, longevity treatment, disease prevention or clinical use.
What Is FOXO4-DRI?
FOXO4-DRI is an experimental peptide designed to investigate protein interactions associated with cellular senescence.
The name refers to a peptide associated with the FOXO4 protein and a D-retro-inverso design.
Understanding FOXO4
FOXO4 belongs to the forkhead box O family of transcription factors.
FOXO proteins participate in several cellular regulatory processes.
Relevant research topics include:
- Cellular stress responses.
- Gene expression regulation.
- Cell-cycle-associated pathways.
- Oxidative stress signalling.
- Apoptosis-associated mechanisms.
- Cellular survival regulation.
- Senescence-associated biology.
These processes provide the scientific background for FOXO4-related research.
Understanding p53
p53 is a protein involved in regulating cellular responses to DNA damage and other stressors.
It participates in several important biological processes, including:
- DNA damage responses.
- Cell-cycle regulation.
- Cellular senescence.
- Apoptosis.
- Cellular stress signalling.
- Gene expression.
- Tissue homeostasis.
The activity of p53 depends on cellular context and interactions with other proteins.
What Does D-Retro-Inverso Mean?
A D-retro-inverso peptide is a designed peptide in which the amino acid sequence is reversed and D-amino acids are used in place of the corresponding L-amino acids.
This design can preserve aspects of the spatial presentation of side chains while changing the peptide backbone’s stereochemical properties.
D-retro-inverso design is investigated in peptide chemistry because it can alter characteristics such as proteolytic susceptibility and molecular interactions.
However, D-retro-inverso peptides are not necessarily biologically identical to their original L-peptide counterparts.
The exact FOXO4-DRI sequence, stereochemistry, terminal modifications and any additional functional components must be verified against the applicable product documentation.
FOXO4-DRI and Senescent Cells
Senescent cells undergo changes in cellular signalling and gene expression.
Some senescent cells also exhibit altered resistance to apoptosis.
Published preclinical research has investigated whether disrupting FOXO4–p53 interactions affects the survival of selected senescent-cell populations.
These investigations contribute to understanding senescence-associated cell survival.
However, the findings are context-dependent and do not establish clinical senolytic efficacy.
FOXO4-DRI Peptide Research and Scientific Applications
Published research involving FOXO4-DRI spans cellular senescence, protein interaction biology, apoptosis-associated signalling and experimental tissue responses.
The following sections describe scientific research topics rather than proven therapeutic effects of the Peps Aussie material.
1. Cellular Senescence Research
One of the primary areas associated with FOXO4-DRI research involves cellular senescence.
Cellular senescence is a complex biological state associated with stable cell-cycle arrest and changes in cellular function.
Relevant research topics include:
- Senescence-associated cell-cycle arrest.
- Cellular stress responses.
- Senescence-associated gene expression.
- Senescent-cell survival.
- Experimental senescence models.
- Cellular ageing-associated pathways.
- Comparative cellular assays.
These investigations contribute to understanding the biological characteristics of senescent cells.
However, changes observed in experimental senescence models do not establish anti-ageing effects in humans.
2. FOXO4–p53 Protein Interaction Research
FOXO4-DRI was designed to investigate the interaction between FOXO4 and p53.
Protein–protein interactions play important roles in regulating cellular signalling and stress responses.
Relevant research topics include:
- FOXO4-associated signalling.
- p53-associated regulatory pathways.
- Protein–protein interactions.
- Experimental interaction disruption.
- Cellular stress signalling.
- Molecular binding studies.
- Comparative peptide activity.
These investigations contribute to understanding how FOXO4 and p53 may influence senescent-cell biology.
However, the precise effects of disrupting this interaction depend on cellular context and experimental conditions.
3. Apoptosis and Senescent-Cell Survival Research
Apoptosis is a regulated form of programmed cell death.
Some senescent cells exhibit altered survival signalling that may affect their susceptibility to apoptosis.
FOXO4-DRI has been investigated in preclinical models involving senescent-cell survival.
Relevant research topics include:
- Apoptosis-associated signalling.
- Senescent-cell survival mechanisms.
- p53-associated pathways.
- Cellular stress responses.
- Experimental cell death assays.
- Comparative cellular susceptibility.
- Molecular regulatory mechanisms.
These investigations contribute to understanding apoptosis regulation in senescent cells.
However, experimental cell death does not establish selective or safe senescent-cell elimination in humans.
4. Senolytic Research
The term senolytic refers to an experimental approach intended to selectively eliminate senescent cells.
FOXO4-DRI has been discussed in preclinical senolytic research.
Relevant research topics include:
- Senescent-cell targeting.
- Differential cellular susceptibility.
- Apoptosis-associated mechanisms.
- Experimental senolytic activity.
- Cellular viability measurements.
- Comparative senescence models.
- Selectivity assessment.
These investigations contribute to understanding potential approaches for studying senescent-cell survival.
However, the designation senolytic does not establish clinical efficacy, safety or therapeutic suitability.
5. Senescence-Associated Secretory Phenotype Research
Some senescent cells exhibit a senescence-associated secretory phenotype, commonly abbreviated SASP.
The SASP can involve the production of cytokines, chemokines and other signalling molecules.
Relevant research topics include:
- Senescence-associated secretory factors.
- Inflammatory signalling.
- Cytokine-associated pathways.
- Cellular communication.
- Experimental tissue models.
- Senescence-associated gene expression.
- Molecular regulatory mechanisms.
These investigations contribute to understanding the relationship between senescent cells and their surrounding environment.
However, SASP characteristics vary between cell types and experimental conditions.
6. Experimental Tissue and Ageing-Associated Research
FOXO4-DRI has been investigated in animal models involving senescence-associated tissue changes.
These studies have explored selected cellular and tissue-related outcomes.
Relevant research topics include:
- Experimental ageing models.
- Senescence-associated tissue changes.
- Cellular stress responses.
- Tissue-associated signalling.
- Histological observations.
- Molecular biomarkers.
- Comparative animal studies.
These investigations contribute to understanding senescence-associated tissue biology.
However, findings from animal models do not establish that FOXO4-DRI reverses biological ageing or improves lifespan in humans.
7. FOXO4-DRI Compared With Other Senescence Research Compounds
FOXO4-DRI is sometimes discussed alongside other compounds investigated in cellular senescence research.
However, these compounds may act through different molecular mechanisms.
FOXO4-DRI:
- A designed D-retro-inverso peptide.
- Investigated in relation to FOXO4–p53 interactions.
- Associated with experimental senescent-cell survival research.
- Requires verification of the supplied sequence and stereochemistry.
Dasatinib and Quercetin Research:
- Involves chemically distinct compounds.
- Has been investigated in senescence-related experimental models.
- May affect different cellular pathways.
- Should not be considered mechanistically equivalent to FOXO4-DRI.
Other Experimental Senolytic Compounds:
- May target different survival mechanisms.
- Can have distinct chemical structures.
- May be investigated in different cell populations.
- Require independent evaluation of selectivity and safety.
Research findings involving one compound should not automatically be attributed to another.
8. FOXO4-DRI Analytical Characterisation and Quality Research
FOXO4-DRI is also relevant to analytical investigations involving peptide identity, stereochemistry and material quality.
Laboratories evaluating FOXO4-DRI may investigate:
- Confirmation of the declared peptide identity.
- Amino acid sequence verification.
- D-amino acid stereochemistry.
- Retro-inverso sequence orientation.
- Terminal modifications.
- Molecular mass determination.
- Chromatographic purity profiles.
- Related peptide impurities.
- Quantitative content determination.
- Stability and degradation characteristics.
- Batch-to-batch analytical consistency.
Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS), chiral analysis and other suitable methods.
Because FOXO4-DRI uses a D-retro-inverso design, analytical verification should consider both sequence orientation and stereochemistry.
A chromatographic purity result alone does not establish the complete peptide identity, stereochemistry or quantitative content.
Analytical identity, purity and content are separate characteristics that should be evaluated using appropriate methods.
FOXO4-DRI 10mg Research Peptide Specifications
Peps Aussie lists FOXO4-DRI in a nominal 10mg size.
| Specification | Details |
|---|---|
| Product name | FOXO4-DRI |
| Listed size | 10mg |
| Peptide type | Designed D-retro-inverso peptide |
| Research category | Cellular senescence research |
| Primary research association | FOXO4–p53 protein interaction |
| Research areas | Senescent-cell survival, apoptosis and senescence-associated tissue biology |
| Exact amino acid sequence | Requires verification |
| D-amino acid stereochemistry | Requires verification |
| Terminal modifications | Require verification |
| Molecular mass | Requires verification |
| Supplier | Peps Aussie Australia |
| Intended use | Laboratory research and analytical investigation only |
The scientific characteristics above describe FOXO4-DRI as discussed in published research. They do not independently verify the identity, composition, purity or content of the supplied material.
Exact amino acid sequence, stereochemistry, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients should be confirmed against the applicable product label and supporting lot documentation.
Important: The D-retro-inverso design is a defining characteristic of FOXO4-DRI. A peptide with an incorrect sequence orientation or stereochemistry should not automatically be considered equivalent to the published research compound.
FOXO4-DRI Certificate of Analysis (COA) and Quality Documentation
Analytical verification is an important consideration when evaluating synthetic research peptides.
Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.
View Peps Aussie Certificates of Analysis
When evaluating FOXO4-DRI analytical documentation, researchers should consider:
- Peptide identity: Whether testing supports the declared FOXO4-DRI identity.
- Sequence verification: Whether the expected amino acid sequence has been established.
- Stereochemistry: Whether the D-amino acid configuration has been verified.
- Sequence orientation: Whether the retro-inverso design has been characterised.
- Terminal modifications: Whether relevant structural features have been identified.
- Molecular mass: Whether testing supports the expected molecular characteristics.
- Purity assessment: Whether suitable methods were used to evaluate impurities.
- Content determination: Whether quantitative testing supports the declared 10mg quantity.
- Batch traceability: Whether the certificate corresponds to the supplied production lot.
- Testing methodology: Whether the analytical techniques are appropriate for the peptide.
- Additional testing: Whether relevant contamination or other quality assessments were performed.
High-performance liquid chromatography and mass spectrometry are commonly used in peptide characterisation.
However, a general purity result does not independently establish complete peptide identity, sequence orientation, stereochemistry or quantitative content.
A certificate should be interpreted according to the tests actually performed.
The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.
FOXO4-DRI Storage and Laboratory Handling
Research peptides require appropriate handling to support sample integrity and experimental reproducibility.
Storage requirements for FOXO4-DRI depend on its molecular structure, stereochemistry, formulation, packaging and validated manufacturer stability information.
Laboratories should consider:
- Appropriate storage temperature.
- Protection from light and moisture where necessary.
- Suitable laboratory containers.
- Compatibility with analytical solvents.
- Stability following sample preparation.
- Potential degradation during storage.
- Appropriate laboratory handling and disposal procedures.
No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.
Although D-retro-inverso design may alter susceptibility to some forms of enzymatic degradation, this does not establish the storage stability of a particular FOXO4-DRI preparation.
All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.
FOXO4-DRI 10mg Australia – Product Availability and Shipping
Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.
FOXO4-DRI 10mg is the currently listed nominal product size.
Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.
For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.
Frequently Asked Questions About FOXO4-DRI
What is FOXO4-DRI?
FOXO4-DRI is a designed D-retro-inverso peptide investigated for its potential to interfere with FOXO4–p53 interactions in senescent cells.
What is FOXO4-DRI studied for?
Published preclinical research has examined FOXO4-DRI in relation to cellular senescence, senescent-cell survival, apoptosis-associated signalling and senescence-associated tissue changes.
What does D-retro-inverso mean?
D-retro-inverso describes a peptide design involving reversed amino acid sequence orientation and D-amino acid stereochemistry.
What is FOXO4?
FOXO4 is a transcription factor involved in cellular stress responses, gene expression and other regulatory processes.
What is p53?
p53 is a protein involved in cellular stress responses, DNA damage signalling, cell-cycle regulation and apoptosis.
What is the FOXO4–p53 interaction?
The FOXO4–p53 interaction is a protein-associated regulatory relationship investigated in cellular senescence research.
Is FOXO4-DRI a senolytic?
FOXO4-DRI has been investigated as an experimental senolytic candidate in preclinical models. This does not establish clinical senolytic efficacy or safety.
What are senescent cells?
Senescent cells are cells that have entered a relatively stable state of cell-cycle arrest and may exhibit changes in signalling, metabolism and secretory activity.
Does FOXO4-DRI remove senescent cells?
Preclinical studies have examined senescent-cell responses to FOXO4-DRI. However, these findings do not establish that the Peps Aussie material selectively or safely eliminates senescent cells in humans.
Does FOXO4-DRI reverse ageing?
There is no established human clinical evidence demonstrating that FOXO4-DRI reverses ageing.
Does FOXO4-DRI extend lifespan?
Human lifespan extension has not been established for FOXO4-DRI.
Is FOXO4-DRI approved for human use?
No medical approval or clinical suitability is claimed for the Peps Aussie FOXO4-DRI research product.
What size does Peps Aussie list?
Peps Aussie lists FOXO4-DRI in a 10mg nominal size. Researchers should verify the individual product label and supporting analytical documentation.
Does FOXO4-DRI have a Certificate of Analysis?
Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should confirm that any applicable certificate corresponds to the specific production lot and evaluate the tests performed.
How should FOXO4-DRI be stored?
Storage requirements depend on the peptide’s molecular structure, formulation and validated stability characteristics. Follow the manufacturer’s product-specific documentation and established laboratory procedures.
Is FOXO4-DRI approved for veterinary use?
No veterinary approval or clinical suitability is claimed for the Peps Aussie research product.
It is not supplied for animal consumption, administration, diagnosis, prevention or treatment.
FOXO4-DRI Research Peptides at Peps Aussie Australia
Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and cellular signalling.
FOXO4-DRI remains a subject of scientific interest because of its association with FOXO4–p53 interactions, senescent-cell survival and experimental senescence biology.
Researchers evaluating FOXO4-DRI 10mg should prioritise accurate peptide identification, stereochemical verification, appropriate analytical documentation, batch traceability and validated laboratory procedures.
Explore the Peps Aussie research catalogue at pepsaussie.com.
Research Use Only Disclaimer
FOXO4-DRI 10mg is intended strictly for laboratory research and analytical purposes only.
This product is not intended for human or animal consumption, injection, administration, anti-ageing applications, longevity treatment, disease prevention, therapeutic use or clinical treatment.
Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish senescent-cell clearance, biological age reversal, lifespan extension, improved tissue function, clinical safety or therapeutic suitability for the material offered.
Findings involving experimental FOXO4-DRI preparations should not be assumed to apply to independently supplied research material without verified sequence, stereochemistry, formulation and direct supporting evidence.
No dosing, self-administration or therapeutic guidance is provided.

Reviews
There are no reviews yet.